Eli Lilly Comes Out Swinging

The annual J.P. Morgan Healthcare conference in San Francisco concluded last week with very few big deal announcements. In January 2019, Bristol-Myers Squibb (NYSE: BMY) made its $74 billion takeover of Celgene Corporation (NASDAQ: CELG) public just before the conference started. That was quickly followed by Eli Lilly and Company‘s (NYSE: LLY) $8 billion deal […]

Eli Lilly Acquires Loxo Oncology in its Largest Deal Yet

Eli Lilly and Company (NYSE: LLY) hit the new year running when it announced the acquisition of Loxo Oncology, Inc. (NASDAQ: LOXO), a biopharmaceutical company that develops medicines for genomically defined cancers. Under the terms of the deal, Lilly will acquire all outstanding shares of Loxo for $235.00 per share, or $8 billion. The offer […]


Eli Lilly Doubles Down on Immuno-Oncology

ARMO BioSciences (NASDAQ: ARMO) is a late-stage immuno-oncology company that develops a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors. On a trailing 12-month basis, it generated a net loss of $42.4 million. Eli Lilly and Company (NYSE: LLY) overlooked the loss as […]

MCOs Make Deals to Combat High Drug Costs

Drug companies and managed care organizations are working to keep prices from rising precipitously. Then there’s Pfizer.

Pharmaceutical Deals Celebrate the New Year

The Pharmaceutical sector hasn’t wasted any time getting busy in the New Year. As of January 18, 2017, 10 pharma deals have been announced, with disclosed prices totaling $7.18 billion. Of course, the annual JP Morgan Healthcare Summit, held this year from January 9 to January 13, helped to boost the announcements. The largest deal so […]